Search

EP-4736864-A1 - COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE COMPRISING A GERMINATED OAT EXTRACT

EP4736864A1EP 4736864 A1EP4736864 A1EP 4736864A1EP-4736864-A1

Abstract

The present invention relates to a composition for preventing, alleviating, or treating inflammatory bowel disease, comprising a germinated oat (Avena sativa L.) extract. The composition improves intestinal permeability and enhances tight junction integrity in an inflamed intestinal environment, and thus can be effectively used in the manufacture of a pharmaceutical, health functional food, food or prebiotics for the prevention, alleviation, or treatment of inflammatory bowel disease.

Inventors

  • PYEE, JAE HO

Assignees

  • INGR Inc.

Dates

Publication Date
20260506
Application Date
20251029

Claims (15)

  1. A pharmaceutical composition for use in the prevention or treatment of inflammatory bowel disease (IBD), comprising a germinated oat (Avena sativa L.) extract and a pharmaceutically acceptable carrier.
  2. The pharmaceutical composition for use according to claim 1, wherein the inflammatory bowel disease is at least one selected from the group consisting of ulcerative colitis (UC), Crohn' s disease (CD), irritable bowel syndrome, intestinal Behcet' s disease, indeterminate colitis, infectious enteritis, bacterial enteritis, viral enteritis, amoebic enteritis, hemorrhagic rectal ulcer, ischemic bowel disease, radiation enteritis, tuberculous enteritis, and leaky gut syndrome.
  3. The pharmaceutical composition for use according to claim 1 or 2, wherein the germinated oat is obtained by germinating oat seeds under a light-dark cycle of 2:1 for 1 to 3 days, followed by treatment with an inducer under a light-dark cycle of 2:1 for 2 to 5 days.
  4. The pharmaceutical composition for use according to claim 3, wherein the inducer is abscisic acid, methyl jasmonate, or a combination thereof.
  5. The pharmaceutical composition for use according to any one of claims 1 to 4, wherein the germinated oat extract is prepared by a method comprising: 1) extracting germinated oat with an extraction solvent; and 2) filtering the extract obtained in step 1), and concentrating or drying the filtered extract, wherein the extraction solvent of step 1) is at least one solvent selected from the group consisting of water and an organic solvent, and wherein the drying of step 2) is performed by spray-drying.
  6. The pharmaceutical composition for use according to claim 5, wherein the organic solvent is at least one selected from the group consisting of a C1-C5 alcohol, ethyl acetate, acetone, ether, chloroform, benzene, hexane, and dichloromethane.
  7. The pharmaceutical composition for use according to any one of claims 1 to 6, wherein the germinated oat extract is characterized by improving intestinal permeability and tight junction (TJ) integrity impaired by inflammatory bowel disease.
  8. The pharmaceutical composition for use according to any one of claims 1 to 6, wherein the germinated oat extract promotes the growth of beneficial intestinal microorganisms.
  9. The pharmaceutical composition for use according to claim 8, wherein the beneficial microorganism is at least one lactic acid bacterium selected from the group consisting of Lactobacillus plantarum and Lactobacillus delbrueckii.
  10. A health functional food composition for the prevention or alleviation of inflammatory bowel disease (IBD), comprising a germinated oat (Avena sativa L.) extract.
  11. The health functional food composition according to claim 10, wherein the inflammatory bowel disease is at least one selected from the group consisting of ulcerative colitis (UC), Crohn' s disease (CD), irritable bowel syndrome, intestinal Behcet' s disease, indeterminate colitis, infectious enteritis, bacterial enteritis, viral enteritis, amoebic enteritis, hemorrhagic rectal ulcer, ischemic bowel disease, radiation enteritis, tuberculous enteritis, and leaky gut syndrome.
  12. The health functional food composition according to claim 10 or 11, wherein the germinated oat extract is characterized by improving intestinal permeability and tight junction (TJ) integrity impaired by inflammatory bowel disease.
  13. The health functional food composition according to any one of claims 10 to 12, wherein the health functional food is in a formulation selected from the group consisting of tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jellies, bars, beverages, gums, and candies.
  14. A food composition for the prevention or alleviation of inflammatory bowel disease (IBD), comprising a germinated oat (Avena sativa L.) extract.
  15. A prebiotic composition for improving intestinal microbiota, comprising a germinated oat (Avena sativa L.) extract as an active ingredient.

Description

[Technical Field] The present invention relates to a composition for preventing or treating inflammatory bowel disease, comprising a germinated oat extract with an increased avenanthramide content. [Background Art] Inflammatory bowel disease (IBD) refers to a chronic inflammatory disorder in which inflammation or ulcers occur in the intestine due to unknown causes, including ulcerative colitis (UC), Crohn' s disease (CD), and Behcet' s disease. Patients with inflammatory bowel disease are common worldwide and have shown a markedly increasing trend in recent years in Korea; however, the causes and mechanisms of the disease are relatively complex and have not yet been clearly elucidated. Conventional drugs used for the treatment of inflammatory bowel disease include steroidal immunosuppressants, 5-aminosalicylic acid (5-ASA) based drugs, such as sulfasalazine, which block the production of prostaglandins, and mesalazine. As exemplified above, anti-inflammatory agents and immunosuppressants are prescribed; however, they are associated with side effects such as nausea, vomiting, headache, hemolytic anemia, and male infertility. In addition, a considerable number of patients either do not respond to the treatment or experience reduced efficacy, and thus there is a continuing demand for the development of safer and more effective therapeutics. Inflammatory bowel disease is characterized by damage to the integrity of the epithelial barrier caused by inflammation. Increased permeability of the epithelial tight junctions and impaired barrier integrity lead to weakening of the intestinal barrier, which is referred to as a "leaky gut." Recent studies have revealed that the intestinal barrier plays an important role not only in inflammatory bowel disease but also in various diseases, including autoimmune disorders associated with barrier integrity. Maintaining and strengthening barrier integrity is important for the prevention and treatment of inflammatory bowel disease as well as other diverse diseases. Recently, natural bioactive substances known for their anti-inflammatory effects have attracted attention as important potential therapeutics for the treatment of inflammatory bowel disease. Oat (Avena sativa L.) contains abundant bioactive components and exhibits various health-promoting effects, including antioxidant, antidiabetic, antibacterial, anticancer, antihypertensive, immunomodulatory, antihyperlipidemic, anti-obesity, cardioprotective, and anti-inflammatory effects. According to prior studies, germinated oat has been reported to regulate the expression of junction proteins in the skin, enhance skin barrier function, and treat conditions of skin barrier disruption, thereby exhibiting efficacy against atopic dermatitis. Oat contains various phenolic compounds, among which avenanthramides (AVNs) are a type of phenolic alkaloid represented by the following Chemical Formula I, and are specifically contained in oat. The contents of avenanthramides and phenolic compounds in germinated oat are significantly higher than those in ungerminated oat seeds. Avenanthramides are known to be potent antioxidants and have been reported to exhibit effects such as blood pressure regulation, inhibition of skin irritation, and anti-atherosclerotic activity. Recently, they have also been found to be useful in the treatment of hearing loss and neurodegenerative diseases. As such, research on the applications of avenanthramides has been actively conducted, and they are attracting attention as valuable components that can be used in the treatment of various diseases. However, in the context of inflammatory bowel disease (IBD), the specific effects of active components of germinated oat on intestinal permeability and tight junction (TJ) integrity have not been clearly elucidated. Accordingly, the present inventors conceived inflammatory bowel disease (IBD) as a phenotype associated with the interaction between bioactive compounds of germinated oat and the genetic and proteomic environment determining tight junction integrity, and adopted an integrated approach combining bioinformatics analysis, chemical profiling, and an initial in silico evaluation using the Combination-Oriented Natural Product Database with Unified Terminology (COCONUT). In addition, by focusing on the efficacy evaluation through in silico predictions validated with an in vitro model using Caco-2 cells, the present inventors elucidated the underlying mechanism of the effect of germinated oat on intestinal permeability, and confirmed that a germinated oat extract (GOE) improves tight junction integrity in an inflamed intestinal environment, thereby completing the present invention. [Prior Art Documents] [Patent Documents] (Patent Document 0001) Korean Registration Patent No. 10-1745734(Patent Document 0002) Korean Registration Patent No. 10-1935500 [Disclosure of the Invention] [Problem to be Solved by the Invention] The object of the present invention, which was conc